Pfizer said the FDA has given its experimental leukemia med inotuzumab ozogamicin a priority review as it gets to work on assessing the medication for approval.

Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma candidate Betalutin.

The biotech's CEO says the clinical trial is the first to show that it is possible to usher large-molecule drugs across the blood-brain barrier.

After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib…

Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the…

Takeda and TiGenix have presented 52-week data on their stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas.

In an interview with Bloomberg published yesterday, Sage CEO Jeff Jonas was quoted as saying his company was at the top of everyone’s buying list, sending its…

Gilead has sold a phase 2-ready addiction candidate to Amygdala Neurosciences.

J&J's vet Ross has left for Henry Shein, House E&C Committee staff director Andres takes public affairs job at BIO, and Infinity's Kutok has…

uniQure plans to start a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance…

Biotech